Caribou Biosciences

$8.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Caribou Biosciences

Caribou Biosciences, Inc. is a United States-based clinical-stage biotechnology company. The Company uses clustered regularly interspaced short palindromic repeats (CRISPR) genome editing to discover and develop immune cell-based therapeutics for cancer. It is focused on developing a pipeline of genome-edited off-the-shelf CAR-T cell and natural killer (NK) cell therapies for a range of tumor types. It also offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics and industrial biotechnology. The Company's pipeline includes CB-010, CB-011, CB-012 and CB-020.

Stock Analysis

last close $8.55
1-mo return 51.1%
3-mo return 9.9%
avg daily vol. 479.59T
52-week high 32.65
52-week low 4.89
market cap. $519M
forward pe -
annual div. -
roe -43.4%
ltg forecast -
dividend yield -
annual rev. $11M
inst own. 59.8%

Subscribe now for daily local and international financial news